TY - JOUR
T1 - International Dermatology Outcome Measures (IDEOM)
T2 - A Report From the 2023 Annual Meeting
AU - Zhang, Arianna J.
AU - Ball, Gretchen
AU - Zundell, Melissa
AU - Agüero, Rosario
AU - Yee, Danielle
AU - Shields, Ali
AU - Asare, Christina
AU - Navrazhina, Kristina
AU - Liu, Winston
AU - Foolad, Negar
AU - Kwock, Jeffery
AU - Tejwani, Priyanka
AU - Hamade, Hassan
AU - Jaleel, Tarannum
AU - Butler, Daniel
AU - Silverberg, Nanette
AU - Nattkemper, Leigh
AU - Siegel, Daniel M.
AU - Tan, Jerry
AU - Kim, Brian S.
AU - Larocca, Cecilia
AU - Shinohara, Michi M.
AU - Ehlert, Athena
AU - Latella, John
AU - Guttman-Yassky, Emma
AU - Krueger, James G.
AU - Strand, Vibeke
AU - Armstrong, April W.
AU - Merola, Joseph F.
AU - Perez-Chada, Lourdes
AU - Gottlieb, Alice B.
N1 - Publisher Copyright:
© 2024 Journal of Drugs in Dermatology. All rights reserved.
PY - 2024/12
Y1 - 2024/12
N2 - Background: International Dermatology Outcome Measures (IDEOM) is a non-profit organization whose mission is to improve the availability of evidence-based, consensus-driven outcome measures for dermatological diseases. IDEOM facilitates collaboration between stakeholders from various backgrounds, including researchers, patients, physicians, and industry representatives, to develop objective benchmark metrics that enable better treatment and management of dermatologic conditions. Summary: The 2023 IDEOM Annual Meeting was held June 23-24, 2023. Workgroups in psoriatic disease, hidradenitis suppurativa, geriatric dermatology, connective tissue disease, vitiligo, itch, actinic keratosis, acne, and cutaneous T-cell lymphoma discussed the progress of their respective outcome-measures research. This report summarizes each workgroup’s updates since the 2022 annual meeting and their next steps as established during the 2023 IDEOM Annual Meeting.
AB - Background: International Dermatology Outcome Measures (IDEOM) is a non-profit organization whose mission is to improve the availability of evidence-based, consensus-driven outcome measures for dermatological diseases. IDEOM facilitates collaboration between stakeholders from various backgrounds, including researchers, patients, physicians, and industry representatives, to develop objective benchmark metrics that enable better treatment and management of dermatologic conditions. Summary: The 2023 IDEOM Annual Meeting was held June 23-24, 2023. Workgroups in psoriatic disease, hidradenitis suppurativa, geriatric dermatology, connective tissue disease, vitiligo, itch, actinic keratosis, acne, and cutaneous T-cell lymphoma discussed the progress of their respective outcome-measures research. This report summarizes each workgroup’s updates since the 2022 annual meeting and their next steps as established during the 2023 IDEOM Annual Meeting.
UR - http://www.scopus.com/inward/record.url?scp=85211688599&partnerID=8YFLogxK
U2 - 10.36849/JDD.8363
DO - 10.36849/JDD.8363
M3 - Article
C2 - 39630678
AN - SCOPUS:85211688599
SN - 1545-9616
VL - 23
SP - 1114
EP - 1120
JO - Journal of Drugs in Dermatology
JF - Journal of Drugs in Dermatology
IS - 12
ER -